Profile data is unavailable for this security.
About the company
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its pipeline also includes breast and other cancers. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, Ga-DOTA-RM2, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol.
- Revenue in USD (TTM)1.50bn
- Net income in USD427.61m
- Incorporated2007
- Employees834.00
- LocationLantheus Holdings Inc331 Treble Cove RdNORTH BILLERICA 01862United StatesUSA
- Phone+1 (978) 671-8001
- Fax+1 (302) 636-5454
- Websitehttps://www.lantheus.com/
Mergers & acquisitions
Acquired company | LNTH:NMQ since announced | Transaction value |
---|---|---|
Meilleur Technologies Inc | -29.25% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Envista Holdings Corp | 2.50bn | -1.34bn | 3.68bn | 12.80k | -- | 1.20 | -- | 1.47 | -7.77 | -7.77 | 14.51 | 17.86 | 0.4106 | 4.21 | 6.19 | 195,570.30 | -21.93 | 1.94 | -25.27 | 2.34 | 54.20 | 57.65 | -53.42 | 5.29 | 1.77 | 3.13 | 0.3163 | 0.00 | -0.1012 | -2.04 | -142.10 | -- | -4.22 | -- |
DENTSPLY SIRONA Inc | 3.90bn | -413.00m | 3.71bn | 15.00k | -- | 1.49 | -- | 0.9501 | -2.07 | -2.07 | 18.91 | 12.53 | 0.5641 | 2.94 | 5.91 | 260,000.00 | -5.93 | -1.14 | -7.41 | -1.32 | 52.18 | 53.65 | -10.51 | -2.51 | 0.8444 | 3.21 | 0.471 | -- | 1.10 | -0.1071 | 86.11 | -- | -4.54 | 9.86 |
Guardant Health Inc | 692.26m | -512.41m | 3.83bn | 1.78k | -- | -- | -- | 5.53 | -4.24 | -4.24 | 5.70 | -0.488 | 0.415 | 3.68 | 7.81 | 389,126.50 | -30.72 | -22.26 | -35.19 | -24.59 | 60.31 | 64.62 | -74.02 | -97.07 | 5.85 | -8.04 | 1.06 | -- | 25.45 | 44.14 | 26.76 | -- | 0.2786 | -- |
ICU Medical Inc | 2.34bn | -111.01m | 4.12bn | 14.00k | -- | 2.02 | 36.20 | 1.76 | -4.57 | -4.57 | 96.31 | 83.76 | 0.5391 | 2.16 | 13.94 | 167,149.80 | -2.56 | 1.46 | -2.90 | 1.65 | 32.87 | 34.11 | -4.74 | 2.23 | 1.03 | 0.5158 | 0.4382 | 0.00 | -0.9154 | 10.04 | 60.08 | -- | -1.45 | -- |
Haemonetics Corporation | 1.36bn | 123.81m | 4.29bn | 3.66k | 35.48 | 4.90 | 18.39 | 3.15 | 2.41 | 2.41 | 26.48 | 17.44 | 0.6001 | 1.87 | 7.02 | 372,224.00 | 5.46 | 5.02 | 6.19 | 6.07 | 54.02 | 51.74 | 9.10 | 8.11 | 2.09 | 27.43 | 0.5823 | 0.00 | 12.01 | 6.23 | 1.87 | 16.40 | -11.04 | -- |
Integer Holdings Corp | 1.68bn | 114.44m | 4.56bn | 10.50k | 41.89 | 2.81 | 20.60 | 2.71 | 3.24 | 3.22 | 47.87 | 48.33 | 0.5594 | 4.93 | 5.14 | 160,023.80 | 3.81 | 3.28 | 4.10 | 3.53 | 27.06 | 26.94 | 6.81 | 6.40 | 2.09 | 4.11 | 0.4028 | 0.00 | 16.03 | 5.62 | 38.71 | 9.33 | 21.71 | -- |
Procept Biorobotics Corp | 199.84m | -100.06m | 5.11bn | 626.00 | -- | 20.42 | -- | 25.55 | -1.95 | -1.95 | 3.89 | 4.63 | 0.5026 | 1.83 | 3.86 | 319,238.00 | -25.16 | -- | -28.58 | -- | 57.39 | -- | -50.07 | -- | 5.07 | -- | 0.1758 | -- | 81.55 | -- | -21.51 | -- | -- | -- |
Inspire Medical Systems Inc | 755.59m | 33.05m | 5.58bn | 1.01k | 171.11 | 8.01 | 146.81 | 7.38 | 1.09 | 1.09 | 25.15 | 23.25 | 1.05 | 2.46 | 9.37 | 747,372.90 | 4.60 | -11.27 | 5.12 | -12.60 | 84.77 | 84.47 | 4.37 | -13.57 | 6.94 | -- | 0.00 | -- | 53.19 | 65.32 | 52.87 | -- | 148.37 | -- |
Stevanato Group SpA | 1.15bn | 120.12m | 5.94bn | 5.64k | 43.86 | 3.87 | 29.38 | 5.19 | 0.4473 | 0.4473 | 4.26 | 5.07 | 0.5284 | 2.75 | 2.66 | 203,340.60 | 5.54 | -- | 7.39 | -- | 29.20 | -- | 10.48 | -- | 1.21 | 48.53 | 0.2148 | -- | 10.34 | -- | 1.95 | -- | -- | -- |
Lantheus Holdings Inc | 1.50bn | 427.61m | 6.07bn | 834.00 | 14.51 | 5.15 | 12.39 | 4.06 | 6.02 | 6.02 | 21.09 | 16.97 | 0.8383 | 8.28 | 5.09 | 1,794,723.00 | 23.95 | 6.69 | 32.76 | 7.73 | 64.78 | 57.56 | 28.57 | 9.02 | 1.56 | -- | 0.324 | 0.00 | 38.65 | 30.44 | 1,063.86 | 51.81 | 35.48 | -- |
Merit Medical Systems Inc | 1.33bn | 120.04m | 6.12bn | 6.95k | 51.45 | 4.62 | 28.11 | 4.62 | 2.04 | 2.04 | 22.55 | 22.71 | 0.6334 | 2.29 | 7.41 | 190,772.80 | 5.73 | 2.45 | 6.32 | 2.77 | 46.83 | 44.50 | 9.05 | 3.91 | 3.82 | 31.88 | 0.3619 | 0.00 | 9.24 | 7.33 | 26.70 | 15.86 | -11.16 | -- |
Glaukos Corp | 360.35m | -149.57m | 7.77bn | 907.00 | -- | 11.61 | -- | 21.55 | -2.96 | -2.96 | 7.06 | 12.13 | 0.3843 | 1.69 | 7.53 | 397,295.50 | -15.95 | -8.73 | -17.23 | -9.35 | 76.61 | 74.77 | -41.51 | -28.69 | 4.71 | -311.24 | 0.1591 | -- | 11.26 | 11.66 | -35.75 | -- | 14.44 | -- |
Repligen Corp | 622.64m | -17.13m | 7.94bn | 1.78k | -- | 3.94 | 154.72 | 12.75 | -0.3079 | -0.3079 | 11.09 | 36.00 | 0.233 | 1.57 | 5.29 | 349,206.40 | -0.6411 | 4.38 | -0.7032 | 5.03 | 50.37 | 55.43 | -2.75 | 15.91 | 8.76 | -- | 0.2055 | 0.00 | -20.31 | 26.91 | -77.64 | 20.13 | 24.99 | -- |
Bruker Corp | 3.24bn | 304.90m | 8.52bn | 9.71k | 27.11 | 4.72 | 18.05 | 2.63 | 2.07 | 2.07 | 21.89 | 11.92 | 0.6527 | 1.51 | 5.73 | 333,913.70 | 6.12 | 8.38 | 8.14 | 11.40 | 49.31 | 49.85 | 9.38 | 11.39 | 0.7085 | 26.83 | 0.5549 | 9.81 | 17.14 | 9.36 | 44.03 | 18.91 | 16.79 | 4.56 |
Teleflex Inc | 3.03bn | 238.01m | 8.85bn | 14.50k | 37.80 | 1.98 | 17.53 | 2.93 | 5.04 | 5.03 | 64.01 | 96.50 | 0.404 | 2.11 | 6.76 | 208,677.50 | 3.18 | 5.86 | 3.46 | 6.42 | 55.99 | 54.43 | 7.87 | 14.62 | 1.39 | 6.61 | 0.2818 | 15.84 | 6.57 | 3.97 | -1.47 | 12.73 | 2.51 | 0.00 |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 30 Sep 2024 | 7.64m | 11.01% |
The Vanguard Group, Inc.as of 30 Sep 2024 | 7.21m | 10.39% |
Janus Henderson Investors US LLCas of 30 Sep 2024 | 3.54m | 5.10% |
Farallon Capital Management LLCas of 30 Sep 2024 | 2.96m | 4.26% |
SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.52m | 3.63% |
Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 2.14m | 3.09% |
Geode Capital Management LLCas of 30 Sep 2024 | 1.68m | 2.43% |
Westfield Capital Management Co. LPas of 30 Sep 2024 | 1.52m | 2.19% |
Dimensional Fund Advisors LPas of 30 Sep 2024 | 1.25m | 1.80% |
Reinhart Partners, Inc.as of 30 Sep 2024 | 1.24m | 1.79% |